Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525602 · ClinicalTrials.gov registry record · Phase 1
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT01525602 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 74 participants.
The verdict
NCT01525602, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Interventions
- DRUG Paclitaxel
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525602
The ClinicalTrials.gov registry entry for NCT01525602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01525602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525602 about?
NCT01525602 is a clinical study titled "Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors". This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twi...
What is the current status of trial NCT01525602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2012-05. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01525602?
The interventions under investigation include: Paclitaxel (DRUG), PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01525602?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.